Can your genes predict which eye drug works best?
NCT ID NCT06952452
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial is testing whether a person's genetic makeup influences how well they respond to two standard drugs for wet age-related macular degeneration: ranibizumab and bevacizumab. About 630 patients will receive one of the two drugs and be followed for three years. The goal is to see if certain gene variants are linked to better or worse vision outcomes, which could help personalize treatment in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ranibizumab and bevacizumab (anti-VEGF drugs injected into the eye)
What this could lead to
If successful, this could help doctors choose the most effective anti-VEGF drug for each patient based on their genetics, potentially improving vision outcomes and reducing costs.
What could go wrong
This is a large phase 3 trial, but it focuses on genetic markers that may not strongly predict treatment response. The results may not change clinical practice if the genetic links are weak.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WET AGE RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Hospital Universitario de Canarias
RECRUITINGSan Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain
Contact
Contact Email: •••••@•••••
-
Hospital de la Santa Creu i Sant Pau
RECRUITINGBarcelona, Spain
Contact
Contact Email: •••••@•••••
-
Hospital la Esperanza
RECRUITINGBarcelona, Spain
Contact
Contact Email: •••••@•••••
-
Unidad Central de Investigación Clínica y Ensayos Clínicos (UCICEC La Paz)
RECRUITINGMadrid, 28046, Spain
Contact
Contact Email: •••••@•••••